top of page

31/07/19

Antimicrobial treatment challenges in the era of carbapenem resistance

Peri AM, Doi Y, Potoski BA, Harris PN, Paterson DL, Righi E

Infections due to carbapenem-resistant Gram-negative bacteria are burdened by high mortality and represent an urgent threat to address. Clinicians are currently at a dawn of a new era in which antibiotic resistance in Gram-negative bacilli is being dealt with by the availability of the first new antibiotics in this field for many years. Although new antibiotics have shown promising results in clinical trials, there is still uncertainty over whether their use will improve clinical outcomes in real world practice. Some observational studies have reported a survival benefit in carbapenem-resistant Enterobacteriaceae bloodstream infections using combination therapy, often including "old" antibiotics such as colistin, aminoglycosides, tigecycline, and carbapenems. These regimens, however, are linked to increased risk of antimicrobial resistance, and their efficacy has yet to be compared to new antimicrobial options. While awaiting more definitive evidence, antibiotic stewards need clear direction on how to optimize the use of old and novel antibiotic options. Furthermore, carbapenem-sparing regimens should be carefully considered as a potential tool to reduce selective antimicrobial pressure.


Keywords: Antimicrobial stewardship; Carbapenem-resistant Gram-negative bacteria; Carbapenem-sparing; Combination regimens; New antibiotics.

LOGO IDCARE bianco.png
  • Twitter
  • LinkedIn

Borgo Roma-Policlinico G.B. Rossi, Piazzale Antonio Ludovico Scuro, 10, 37134, Verona, Italy.

Borgo Trento-Ospedale Borgo Trento Piazzale Aristide Stefani, 1 - 37126, Verona, Italy

+39 045 8128243

Copyright © 2024 ID-Care.

bottom of page